The arrival of Vertex's (VRTX) Incivek in 2010 kicked off a significant jump in the costs of treating hepatitis C. Those costs are likely to surge higher once Gilead's (GILD) and Johnson & Johnson's (JNJ) new drugs launch.
Merck was a leading decliner within the drugs industry, falling $0.50 (-1.0%) to $48.81 on light volume
Merck has agreed to buy London-listed AZ Electronic Materials SA in a deal valuing the chemicals supplier at $2.96 billion including debt.
Forest Laboratories makes significant company improvements as AstraZeneca considers possible buyout.
TheStreet contributor David Sobek offers seven forecasts for biotech stocks in 2014.
Instead of fuelling the markets, better economic data causes a retreat as investors remain uncertain about an environment with less Fed support.
Newly public Veeva Systems has posted sharp gains since its October debut, with Merck, Gilead Sciences, and others relying on its products. But will its partnership with Salesforce.com keep its impressive customer list growing? Find out here.
This Dow Jones health-care standout has surged this year, but is the worst of the patent cliff over for Merck?
The Dow Jones Industrials started December on a down note, but even its fall didn't keep many stocks from climbing.
A compelling new drug in development from Merck (MRK) has a chance to change melanoma treatment, posing a threat to rapidly growing market share for Bristol Myers' (BMY) Yervoy.
Trade-Ideas LLC identified Merck (MRK) as a momo momentum candidate
The Dow Jones Industrials have pushed sharply higher, and these stocks were the ones doing the heavy lifting. Find out which stocks lifted the most.
Thinking about investing in Johnson & Johnson? Then you need to know these three things before 2014 that could also influence Merck, Hospira, and Pharmacyclics.